Actionable news
0
All posts from Actionable news
Actionable news in RDHL: Redhill Biopharma Ltd.,

Redhill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015 EXHIBIT 99.1

The following excerpt is from the company's SEC filing.

RedHill Biopharma to Present at Gelbart-Kahana Biomed Conference on October 25, 2015

TEL-AVIV, Israel, Oct. 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that Ori Shilo, RedHill's Deputy CEO Finance and Operations, will present at the Gelbart-Kahana Biomed Conference on Sunday, October 25, 2015, at the Tel-Aviv Stock Exchange, Israel.

To participate in the conference please contact Gelbat-Kahana by email at: erang@gk-biz.com, or by telephone: +972-(0)3-6070-59.

A copy of the presentation to be made by Mr. Shilo is available on the Company's website and may be viewed at the following web address: http://ir.redhillbio.com/

About RedHill Biopharma Ltd.:

RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is an emerging Israeli biopharmaceutical company primarily focused on the development of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. RedHill's current pipeline of proprietary products includes: (i)

RHB-105

an oral combination therapy for the treatment of

Helicobacter pylori

infection with successful top-line results from a first Phase III study; (ii)

RHB-104

an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study; (iii)

BEKINDA

(RHB-102)

a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted in December 2014; (iv)

RHB-106

an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v)

YELIVA

(ABC294640)

an orally-administered first-in-class SK2 selective inhibitor targeting multiple oncology...


More